Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 146 participants.

Also called NCT02899455

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 146 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02899455
Other papers using this trial's data
  • A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia Clinical therapeutics, 2017-12 DOI, PubMed 29150250

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02899455. Randomized; double masking; primary purpose treatment. Start 2014-07 (registry gives no type); primary completion 2016-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia
Condition
Hypertension
Condition
Hyperlipidemia
Intervention (Drug)
HGP0904
Intervention (Drug)
HGP0608
Intervention (Drug)
HGP0816
Intervention (Drug)
HGP0904 Placebo
Intervention (Drug)
HGP0816 Placebo
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct02899455
Content hash
c7c4120bd6f9df56b64f655d9bf91ba210d061f1a6afd684a062794777b3c0bf